PHXM — Phaxiam Therapeutics SA Share News
0.000.00%
Last trade - 00:00- €0.61m
- €12.08m
- €1.33m
Europe Research Roundup: Iberdrola, Sodexo, Ubisoft
Erytech Pharma falls after cancer drug fails to extend patient survival
Brief: Erytech Updates On Results Of Trybeca-1 Phase 3 Trial Of Eryaspase
Brief: Erytech Announces Maximum Tolerated Dose Declared In A Phase 1 Investigator Sponsored Trial Oferyaspase In First-Line Pancreatic Cancer
Brief: Erytech Pharma SA Files For Mixed Shelf Of Upto $300 Mln
Brief: Erytech Pharma H1 Net Loss Narrows To 28.0 Million Euros
Brief: Erytech Provides Business Update And Reports Financial Results For First Half Of 2021
NASDAQ RESUMED AT 09:51 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:35 AM
Brief: Erytech Granted U.S. FDA Fast Track Designation For Eryaspase In Hypersensitive All
Brief: Erytech Confirms Plans To Submit BLA For Eryaspase In Hypersensitive All Patients
Brief: Erytech Provides Business Update And Reports Financial Results For The First Quarter Of 2021
Brief: Erytech Announces $30.0 Million Registered Direct Offering
Brief: Erytech Pharma March-End Cash And Cash Equivalents Of EUR 37.4 Millions
Brief: Erytech Requests Pre-BLA Meeting With FDA To Discuss Path To Approval In ALL
Brief: Erytech Completes First Cohort In Phase 1 Investigator Trial Of Eryaspase
Europe Research Roundup: Basic Fit NV, Deutsche Telekom AG, Ferrexpo
Brief: Erytech Pharma FY Operating Loss Widens To EUR 68.8 Mln
Brief: Erytech Announces Trybeca-1 Phase 3 Trial In 2L Pancreatic Cancer To Continue To Final Analysis